• fullslide1
    Addressing vast and
    growing global needs
    in kidney transplantation.
  • fullslide1
    Harnessing the power of
    donor blood cells to protect
    a recipient's new kidneys...
  • fullslide1
    Combining the strengths
    of different cell types
    to make a single
    cellular therapy...
  • fullslide1
    Making the dream of
    transplant immune
    tolerance a reality...


Learn more about our lead product candidate, MDR-101 and other product candidates.

Read More..

News & Publications

See the latest news and publications on kidney transplantation

Read More..

Career Opportunities

Medeor is looking for exceptional individuals who share our vision and passion

Available Positions

About Medeor Therapeutics


MEDEOR THERAPEUTICS is a private, late clinical stage, biotechnology company dedicated to the discovery, development, and commercialization of transformative and personalized cellular immunotherapies. Our growing team of professionals possesses remarkably deep expertise in cellular immunotherapy and transplantation product development. Our pipeline addresses critical medical needs of the approximately 120,000 annual organ transplant recipients worldwide, including greater than 30,000 annual organ transplant recipients in the US alone. Medeor's product candidates are intended to minimize or eliminate chronic anti-rejection, immunosuppressive drug regimens used by new recipients of living donor transplants as well as those who have received a living donor transplant in the past (i.e., 2nd Chance Therapy). We hold exclusive worldwide licenses to a series of breakthrough technologies, all discovered at Stanford University. Medeor is headquartered in San Mateo, California.

Learn More

Senior Management

Dr. Deitcher is an innovative business leader who has more than 25 years of life science product development experience including cellular therapeutics, biologics, small molecules, and diagnostics. He was President, CEO and Board Member at Talon Therapeutics, a specialty biopharmaceutical company focused on novel cancer drug delivery...
Read More

Steven R. Deitcher, M.D.

Founder, President, CEO, and Board Member
Dr. Weber joined Medeor Therapeutics in 2016 to lead all global regulatory and quality efforts related to MDR-101. He has more than 20 years of regulatory affairs experience with biological products. Previously, he was Executive Vice President of Global Regulatory Affairs and Quality Management for Mesoblast LTD. Prior to joining Mesoblast...
Read More

Darin J. Weber, Ph.D.

Senior Vice President, Regulatory Affairs & Quality
Dr. Read joined Medeor Therapeutics in 2015 to lead MDR-101 product development efforts ranging from donor stem cell collection to commercial manufacturing and final product delivery to patients. She has more than 20 years of product development experience with biological products. Previously, Dr. Read held cell therapy ...
Read More

Elizabeth "EJ" Read, M.D.

Senior Vice President, Product Development
Dr. Batty joined Medeor Therapeutics in 2016 as Chief Medical Officer to lead the clinical development and medical affairs efforts related to Medeor's organ transplantation programs. Previously, Scott held an executive management role at ImmunArray as well as leadership roles in transplant and stem cell product clinical development ...
Read More

D. Scott Batty, Jr., M.D

Chief Medical Officer

Learn More About Our Board Members



Medeor is developing groundbreaking cellular immunotherapy products for kidney transplant recipients, called the MDR-10X series. MDR-10X includes, but is not limited to, MDR-101 and MDR-102 for recipients of HLA-matched and HLA-mismatched, living donor transplants, respectively. One time treatment with a MDR-10X product is intended to preserve or improve transplant kidney function and minimize or eliminate the need for chronic anti-rejection drug therapy in kidney transplant recipients. MDR-10X can induce donor-specific immune tolerance that protects against transplant kidney rejection, while avoiding the toxic side-effects of standard anti-rejection, immunosuppressive drugs. MDR-10X is manufactured from stem and progenitor cells collected from the kidney donor and infused into the transplant recipient several days after the transplant surgery. Prior to MDR-10X infusion, the transplant recipient receives conditioning therapy to make room for the MDR-10X cells. Achievement of mixed chimerism, co-existence of donor and recipient blood cells, is at the heart of the MDR-10X mechanism of action.


The MDR-10X series of cellular immunotherapy products, including MDR-101 and MDR-102, are paradigms of personalized and precision medicine. These products are manufactured from living transplant kidney donor-derived stem cells. The cellular source materials are engineered into the final MDR-10X product using patent protected methods and processes. The composition of the final cellular immunotherapy product is a unique formulation of multiple different types of hematopoietic (i.e., blood or bone marrow derived) cells. The doses of CD34+ hematopoietic stem and progenitor cells (HSC) and the CD3+ T cells are critical to the action of the MDR-10X product. Cell doses are guided by the degree of immunologic disparity between the recipient and donor (i.e., degree of human leukocyte antigen (HLA)-match or HLA-mismatch). A single dose of MDR-10X can produce hematologic mixed chimerism. Hematologic mixed chimerism represents the co-existence of both recipient-derived and donor-derived blood and immune cells in the recipient. Mixed chimerism supports clonal deletion and immune regulation, the biologic mechanisms underlying immune tolerance. Essentially, MDR-10X can "reprogram" a kidney transplant recipient's immune system to specifically not react against and potentially destroy the transplant organ itself.